On October 8, 2024, Newland Pharmaceutical Co., Ltd. (hereinafter referred to as "the Company") received the *Approval Notice for the Marketing Application of the Chemical Active Pharmaceutical Ingredient* for Ropivacaine Hydrochloride, approved and issued by the National Medical Products Administration (NMPA). The registration number is Y20220001314, and the notice number is 2024YS01021

On September 24, 2024, Newland Pharmaceutical Co., Ltd. (hereinafter referred to as "the Company") received the Approval Notices for the Marketing Application of Chemical Active Pharmaceutical Ingredients for Esomeprazole Sodium and Tadalafil, approved and issued by the National Medical Products Administration (NMPA).

On the morning of July 12, the company's 2024 first-half work summary meeting was held at the multifunctional hall. Chairman Mr. Xie Jianzhong attended and delivered a speech, Chief Scientist Professor Liu Hongmin took the stage to address the meeting, and General Manager Mr. Zhang Luwei presented a comprehensive summary of the first half of the year. Managers at the mid-level and above atten

On June 17, the second strategy review meeting of Newland Pharmaceutical was held at the company's multifunctional hall. Strategic planning experts attended to provide guidance, and Chairman Mr. Xie Jianzhong was present and gave important instructions on the strategic plan.

On the morning of April 12, the company's Q1 2024 work summary meeting was held in the multifunctional hall. Chairman Xie Jianzhong and Professor Liu Hongmin, the company's Chief Scientist, attended and delivered speeches. General Manager Zhang Luwei and several senior executives presented work reports. The meeting was attended by managers at the middle level and above.